Back to Search
Start Over
Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: A randomized controlled trial.
- Source :
- Journal of Allergy & Clinical Immunology; Aug2012, Vol. 130 Issue 2, p362-367.e9, 0p
- Publication Year :
- 2012
-
Abstract
- Background: Information surrounding the long-term safety of combination inhaled corticosteroid/long-acting β<subscript>2</subscript>-adrenergic agonist medications in African American asthmatic patients is limited. Objective: We sought to assess safety and asthma control with a budesonide/formoterol pressurized metered-dose inhaler (pMDI) versus budesonide over 1 year in African American patients. Methods: This 52-week, randomized, double-blind, parallel-group, multicenter, phase 3B safety study (NCT00419952) was conducted in 742 self-reported African American patients 12 years or older with moderate-to-severe asthma previously receiving medium- to high-dose inhaled corticosteroids. After 2 weeks using a 320 μg twice-daily budesonide pMDI, patients were randomized 1:1 to 320/9 μg twice-daily budesonide/formoterol pMDI or 320 μg twice-daily budesonide pMDI. Results: Both treatments were well tolerated. Asthma exacerbation incidence and rate (per patient-treatment year) were lower with budesonide/formoterol versus budesonide (incidence, 7.7% vs 14.0% [P = .006]; rate ratio, 0.615 [P = .002]). Time to first asthma exacerbation was longer (P = .018) with budesonide/formoterol versus budesonide. The most common adverse events, regardless of study drug relationship, were headache (9.5% and 7.7%), nasopharyngitis (6.9% and 8.0%), sinusitis (4.0% and 6.3%), and viral upper respiratory tract infection (5.8% and 4.4%) for budesonide/formoterol and budesonide, respectively. Serious adverse events occurred in 12 and 15 patients, respectively; none were considered drug related. No substantial or unexpected patterns of abnormalities were observed in laboratory, electrocardiographic, or Holter monitoring assessments. Hospitalization caused by asthma exacerbation occurred in 0 and 4 patients in the budesonide/formoterol and budesonide groups, respectively. Pulmonary function and asthma control measures generally favored budesonide/formoterol. Conclusions: In this population budesonide/formoterol pMDI was well tolerated over 12 months, with a safety profile similar to that of budesonide; the asthma exacerbation rate was reduced by 38.5% versus budesonide. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 00916749
- Volume :
- 130
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Journal of Allergy & Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 78146660
- Full Text :
- https://doi.org/10.1016/j.jaci.2012.03.028